Abdominal mass Biopsy - XL

Biopsy

Report in 288Hrs

At Home

No Fasting Required

Details

Extra- Large biopsy of abdominal mass for histopathology.

₹888₹1,269

30% OFF

Abdominal Mass Biopsy - XL: Comprehensive Medical Test Information Guide

Section 1: Why is it done?
- Test Description: Abdominal Mass Biopsy-XL is a minimally invasive diagnostic procedure that involves extracting tissue samples from an abnormal mass or lesion detected in the abdominal cavity. The 'XL' designation indicates an extended/large tissue sampling approach, providing comprehensive histopathological analysis for precise diagnosis and characterization.
- Primary Indications: Diagnosis of suspicious abdominal masses, including potential malignancies (cancers), benign tumors, inflammatory conditions, infections, or cystic lesions
- Differentiation of Lesion Type: Determining whether masses are malignant, benign, infectious, or inflammatory in nature
- Organ-Specific Investigation: Evaluation of masses in liver, pancreas, kidney, adrenal glands, spleen, bowel, mesentery, peritoneum, or other abdominal structures
- Cancer Staging and Grading: Determining tumor type, grade, stage, and genetic/molecular characteristics for treatment planning
- Typical Timing: Following imaging studies (ultrasound, CT scan, or MRI) that reveal an indeterminate or suspicious abdominal mass requiring tissue confirmation; typically performed within 1-4 weeks of imaging discovery
Section 2: Normal Range
- Interpretation of Normal Results: 'Normal' or 'Negative' indicates absence of malignancy, significant inflammation, or infection; tissue demonstrates benign characteristics consistent with normal organ parenchyma or known benign conditions
- Reference Standards (No Numerical Values): Biopsy results are qualitative rather than quantitative. Pathologists compare tissue characteristics to established histological standards and normal tissue architecture.
- Benign Findings Include: Lipoma, hemangioma, simple cysts, inflammatory hyperplasia, fibrosis, granulomatous inflammation, or non-malignant infections
- Positive/Abnormal Results Include: Malignant cells (carcinoma, sarcoma, lymphoma), evidence of metastatic disease, or significant pathological changes requiring intervention
- Inconclusive Results: Occasionally, biopsy may show atypical or borderline findings requiring additional testing, repeat biopsy, or clinical correlation
- Units of Measurement: Results are descriptive histopathological findings documented in narrative format using standardized pathology terminology and classification systems (WHO, TNM staging)
Section 3: Interpretation
- Benign Diagnoses: Lipoma - benign fatty tumor requiring no treatment; Hemangioma - benign vascular lesion with favorable prognosis; Simple cysts - non-neoplastic fluid collections; Adenomas - benign epithelial tumors generally requiring observation; Inflammatory masses - often managed medically
- Malignant Diagnoses: Adenocarcinoma - most common malignancy requiring surgery and/or chemotherapy; Squamous cell carcinoma - aggressive variant often requiring multimodal therapy; Sarcoma - mesenchymal malignancy with variable prognosis; Lymphoma - hematologic malignancy requiring systemic treatment; Metastatic disease - indicates disseminated cancer requiring palliative/systemic therapy
- Infectious/Inflammatory Findings: Tuberculosis, fungal infections (histoplasmosis, blastomycosis), abscess, granulomatous inflammation - may require antimicrobial therapy or surgical drainage; Cultures performed to identify specific organisms
- Tumor Grade and Stage: Grade 1 (Low) - well-differentiated, slower growth, better prognosis; Grade 2 (Intermediate) - moderately differentiated; Grade 3 (High) - poorly differentiated, aggressive behavior, worse prognosis. TNM staging (Tumor-Node-Metastasis) determines treatment intensity and predicts survival
- Molecular and Genetic Testing: XL biopsy enables comprehensive molecular analysis - immunohistochemistry (IHC) markers, gene mutations (EGFR, KRAS, BRAF), HER2 status, microsatellite instability (MSI), tumor mutational burden (TMB). Results guide targeted therapy, immunotherapy, or clinical trial eligibility
- Factors Affecting Interpretation: Specimen adequacy (size, cellular preservation); Fixation method and timing; Background inflammation or necrosis; Prior treatments (chemotherapy, radiation) may alter histology; Sampling location (central vs peripheral portions of mass)
- Inconclusive or Suspicious Results: May warrant repeat biopsy from different location, imaging follow-up, or clinical observation. Atypical findings require correlation with imaging and clinical presentation for management decisions
Section 4: Associated Organs
- Primary Organ Systems Involved: Hepatobiliary system (liver, bile ducts, gallbladder); Pancreatic system; Gastrointestinal tract (stomach, small bowel, colon); Urinary system (kidneys, ureters); Endocrine system (adrenal glands); Splenic and reticuloendothelial system; Peritoneal and mesenteric structures
- Malignancies Commonly Diagnosed: Hepatocellular carcinoma (HCC); Cholangiocarcinoma; Pancreatic adenocarcinoma; Gastric cancer; Colorectal cancer; Renal cell carcinoma; Adrenocortical carcinoma; Mesothelioma; Lymphomas; Sarcomas; Metastatic tumors from distant primaries
- Benign Conditions Identified: Benign hepatic adenomas and hemangiomas; Pancreatic cystic neoplasms (mucinous or serous cystadenoma); Renal angiomyolipoma; Adrenal adenomas; Splenic cysts or hemangiomas; Mesenteric lymphadenitis; Inflammatory bowel changes
- Infectious Diseases Detected: Tuberculosis (intestinal, mesenteric lymph nodes); Fungal infections (histoplasmosis, blastomycosis, coccidioidomycosis); Bacterial abscess; Parasitic infections; Atypical mycobacterial infections in immunocompromised patients
- Inflammatory and Autoimmune Conditions: Crohn's disease; Ulcerative colitis; Sarcoidosis; Granulomatosis with polyangiitis; Systemic lupus erythematosus involvement; Sclerosing mesenteritis
- Potential Complications from Abnormal Results: Cancer progression and metastasis if untreated; Bowel obstruction from advanced malignancy; Perforation or fistulization in infectious/inflammatory disease; Organ dysfunction (hepatic failure, renal insufficiency, pancreatitis); Peritonitis or sepsis from ruptured infected masses; Vascular compromise from expanding tumors
- Biopsy-Related Risks: Bleeding (1-2% risk, higher if vascular lesion); Infection (<1% risk); Organ perforation; Pancreatitis (if pancreatic biopsy); Bile duct injury; Bowel perforation; Pain or abdominal wall hematoma; Peritoneal seeding of malignant cells (rare)
Section 5: Follow-up Tests
- Imaging Studies: CT chest/abdomen/pelvis for cancer staging; MRI for soft tissue characterization and metastasis detection; PET-CT for metabolic activity and distant metastases; Endoscopic ultrasound (EUS) for additional imaging or biopsy; Follow-up ultrasound for monitoring
- Repeat Biopsy: If initial biopsy inconclusive, non-diagnostic, or shows atypical features; May be performed from different location within mass; Consider if imaging findings and clinical presentation don't match pathology results
- Laboratory Tests: Tumor markers (AFP for hepatocellular carcinoma, CEA for gastrointestinal cancers, CA 19-9 for pancreatic cancer); Complete blood count; Comprehensive metabolic panel; Liver and kidney function tests; Lactate dehydrogenase (LDH); Microbiologic cultures and sensitivities if infection suspected
- Molecular and Genetic Testing: Next-generation sequencing (NGS) for comprehensive genomic profiling; EGFR, KRAS, BRAF mutations for targeted therapy eligibility; HER2 testing for immunotherapy decisions; PD-L1 expression for checkpoint inhibitor response; Microsatellite instability and tumor mutational burden; Circulating tumor DNA (ctDNA) for treatment monitoring
- Cancer Treatment Planning: Surgical consultation for resection; Oncology evaluation for chemotherapy, radiotherapy, or immunotherapy; Interventional radiology consultation for ablative procedures; Multidisciplinary tumor board review
- Post-Treatment Surveillance: Regular imaging (CT, MRI) every 3-6 months for first 2 years; Tumor marker monitoring; Physical examination; Symptoms assessment; Long-term surveillance for recurrence (5-10 years depending on cancer type)
- Infectious Disease Workup: Mycobacterial culture and sensitivity; Fungal culture; Gram stain and bacterial culture; AFB smear; Acid-fast bacilli staining; Serologic testing for specific organisms (TB, fungal serology)
- Inflammatory Condition Evaluation: Inflammatory markers (ESR, CRP); Autoimmune serology (ANA, anti-ANCA); ACE level and serum calcium for sarcoidosis; Corticosteroid or immunosuppressive therapy monitoring
Section 6: Fasting Required?
- Fasting Requirement: YES - Fasting is required for this procedure
- Fasting Duration: NPO (Nothing by mouth) for minimum 6-8 hours before procedure; Typically overnight fast (after midnight if morning procedure); Some centers recommend 8-12 hours fasting for optimal visualization
- Fluid Intake: Clear liquids only may be allowed 2-4 hours before procedure (confirm with ordering physician); Small sips of water often permitted until 2 hours before procedure
- Medications to Avoid: Anticoagulants (warfarin, apixaban, rivaroxaban) - hold 3-5 days before procedure or as directed; Antiplatelet agents (aspirin, clopidogrel) - hold 5-7 days or as directed if bleeding risk significant; NSAIDs - hold 3-5 days before procedure; Direct anticoagulants - coordinate timing with interventional radiologist
- Medications to Continue: Continue all other regular medications with small sip of water (unless otherwise instructed); Blood pressure medications - usually continued with minimal water; Diabetic medications - hold morning dose if fasting; Confirm with physician which medications to take morning of procedure
- Pre-Procedure Patient Instructions: Arrange for responsible adult to drive (sedation/anesthesia typically used); Arrive 30-60 minutes early for registration; Bring insurance card and photo ID; Wear loose, comfortable clothing; Remove jewelry and metal objects; Discuss allergies (especially iodine/contrast) and medical history; Obtain recent lab work (CBC, PT/INR if on anticoagulation, comprehensive metabolic panel)
- Procedural Preparation: IV access established for sedation/anesthesia; Vital signs monitored; Skin preparation at biopsy site; Informed consent verified; Procedural time typically 30-60 minutes depending on lesion location and complexity
- Post-Procedure Restrictions: NPO continued 1-2 hours post-procedure; Gradual resumption of diet starting with clear liquids; No strenuous activity or heavy lifting for 3-7 days; Pain control with prescribed or OTC analgesics as tolerated; Monitor for bleeding, fever, or severe abdominal pain; Follow-up appointment typically within 1-2 weeks for results discussion

How our test process works!